Don't Recommend Spiriva First-Line for Mild COPD

December 2017

New evidence will spark controversy over how to treat COPD patients with MILD disease.

About seven in 10 COPD patients have early disease with minimal symptoms. But meds are usually studied in moderate to severe COPD.

Now evidence suggests that Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA), may be beneficial for mild COPD.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Vaccines Help Patients Understand Differences Between Zostavax II and Shingrix
Cardiology Look for Heart Failure Patients Who May Need an Aldosterone Antagonist
Insulin Consider High-Concentration Entuzity for Insulin-Resistant Patients
COPD Don't Recommend Spiriva First-Line for Mild COPD
Pregnancy Have Confidence Using Generic Diclectin First-Line for Morning Sickness
Supplements Tell Diabetes Patients Not to Rely on Cinnamon
Gastroenterology Explain When to Hold Meds Before Colonoscopy
NSAIDs Recommend a Chronic NSAID Based on Safety
Acne Discourage Using Oral Antibiotics Long-Term for Acne
Infectious Diseases Antibiotics Are Rarely Needed for Acute Infectious Diarrhea
Practice Ensure Your Patients Get In-Date Meds